TrkB receptor inhibitor

DRUG CLASS:

TrkB receptor inhibitor

News alerts, weekly reports and conference planners

Related drugs:

‹

›

ROS1 G2032R	Non Small Cell Lung Cancer	ROS1 G2032R	Non Small Cell Lung Cancer	AB-106 Sensitive: C3 – Early Trials ELCC 2023 - 1 week (New C3) AB-106 Sensitive : C3 ELCC 2023 - 1wk	AB-106 Sensitive: C3 – Early Trials ELCC 2023 - 1 week AB-106 Sensitive : C3 ELCC 2023 - 1 week - (New C3)
ETV6-NTRK3 fusion	Salivary Gland Cancer	ETV6-NTRK3 fusion	Salivary Gland Cancer	entrectinib Resistant: C3 – Early Trials Head Neck - 2 weeks (New C3) entrectinib Resistant : C3 Head Neck - 2wk	entrectinib Resistant: C3 – Early Trials Head Neck - 2 weeks entrectinib Resistant : C3 Head Neck - 2 weeks - (New C3)
ROS1 fusion	Non Small Cell Lung Cancer	ROS1 fusion	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK3 fusion	Sarcoma	NTRK3 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK2 fusion	Sarcoma	NTRK2 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK1 fusion	Sarcoma	NTRK1 fusion	Sarcoma	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK3 fusion	Solid Tumor	NTRK3 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
No biomarker	Solid Tumor	No biomarker	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK2 fusion	Solid Tumor	NTRK2 fusion	Solid Tumor	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
NTRK1 fusion	Solid Tumor	NTRK1 fusion	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
ROS1 positive	Non Small Cell Lung Cancer	ROS1 positive	Non Small Cell Lung Cancer	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1	entrectinib Sensitive: A1 - Approval entrectinib Sensitive : A1
No biomarker	Solid Tumor	No biomarker	Solid Tumor	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1	larotrectinib Sensitive: A1 - Approval larotrectinib Sensitive : A1
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Small Intestinal Carcinoma	NTRK3 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Small Intestinal Carcinoma	NTRK1 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Small Intestinal Carcinoma	NTRK2 fusion	Small Intestinal Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK1 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	NTRK2 fusion	Thyroid Gland Hurthle Cell Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Follicular Carcinoma	NTRK1 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Follicular Carcinoma	NTRK2 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Follicular Carcinoma	NTRK3 fusion	Thyroid Gland Follicular Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Soft Tissue Sarcoma	NTRK3 fusion	Soft Tissue Sarcoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Adenocarcinoma	NTRK2 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Pancreatic Adenocarcinoma	NTRK1 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Gastrointestinal Stromal Tumor	NTRK2 fusion	Gastrointestinal Stromal Tumor	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Breast Cancer	NTRK2 fusion	Breast Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Breast Cancer	NTRK3 fusion	Breast Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Breast Cancer	NTRK1 fusion	Breast Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2

TrkB receptor inhibitor

TrkB receptor inhibitor

Associations(361)

Associations
(361)